# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Source: https://onco.cc/trials/nct07321106/  
OnCo record `nct07321106` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CBI-1214 run by Cartography Biosciences, now recruiting.

## Summary

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer is a phase 1 interventional study registered as NCT07321106 by Cartography Biosciences, with 80 participants planned, started 2026-01-15. Conditions recorded: Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC, Metastatic Colon Cancer, Colon Cancer and Advanced Colorectal Cancer. Interventions recorded: CBI-1214.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07321106
- Phase: 1
- Setting: A Phase 1, First-in-human (FIH), Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer
- Sponsor: Cartography Biosciences
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07321106: https://clinicaltrials.gov/study/NCT07321106

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [CBI-1214](https://onco.cc/drugs/cbi-1214/)
- companies: [Cartography Biosciences](https://onco.cc/companies/cartography-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07321106.json